News
CTMX
1.290
+0.78%
0.010
CytomX Therapeutics Appoints Chris Ogden as New CFO
TipRanks · 4d ago
CytomX Therapeutics promotes Chris Ogden to CFO
CytomX Therapeutics promotes Chris Ogden to CFO effective June 15, 2024. Ogden joined the company after a 16-year tenure at Eli Lilly. CTMX -2.18% after hours to $1.34 in trading on Monday.
Seeking Alpha · 4d ago
*CytomX Therapeutics Promotes Chris Ogden to Chief Fincl Officer >CTMX
Dow Jones · 4d ago
Press Release: CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
Dow Jones · 4d ago
Weekly Report: what happened at CTMX last week (0610-0614)?
Weekly Report · 5d ago
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
CytomX Therapeutics, Inc. Share price has fallen by 30% over the last month. The company's price-to-sales ratio of 0.9x is lower than the industry average for the Biotechs industry. Its revenue growth is expected to slump in the coming years and its P/S is below the industry. CytomXTherapeutics may look like a strong buying opportunity with its low price to sales ratio.
Simply Wall St · 06/15 12:43
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) latest 11% decline adds to one-year losses, institutional investors may consider drastic measures
Institutional investors own 46% of CytomX Therapeutics, Inc. (NASDAQ:CTMX). The company has a large number of shares in the US$116m market cap. 52% of the business is held by the top 11 shareholders of the company. The recent 11% drop in the share price for the company suggests institutional investors may be sensitive to the company's performance. We look at the insider ownership of the firm and its future growth.  CytomXTherapeutics has lost 5.1% of its value in the last year.
Simply Wall St · 06/13 13:25
Weekly Report: what happened at CTMX last week (0603-0607)?
Weekly Report · 06/10 09:16
(CTMX) - Analyzing CytomX Therapeutics's Short Interest
CytomX Therapeutics's short percent of float has risen 143.23% since its last report. The company has 8.75 million shares sold short, which is 11.31% of all regular shares. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 06/05 17:00
Weekly Report: what happened at CTMX last week (0527-0531)?
Weekly Report · 06/03 09:16
Piper Sandler Upgrades CytomX Therapeutics (CTMX)
NASDAQ · 05/28 23:12
CytomX upgraded at Piper Sandler on validation of cancer therapeutics platform
CytomX upgraded at Piper Sandler on validation of cancer therapeutics platform. Analyst says early safety data for CX-904, partnered with Amgen, is encouraging. The firm has a $100 price target for CytomX's lead candidate for solid tumors.
Seeking Alpha · 05/28 13:21
CytomX Therapeutics Price Target Raised to $3.50/Share From $2.25 by Piper Sandler
Dow Jones · 05/28 09:37
CytomX Therapeutics Raised to Overweight From Neutral by Piper Sandler
Dow Jones · 05/28 09:37
Piper Sandler Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $3.5
Benzinga · 05/28 09:27
Stocks Set to Open Higher as Investors Await Key U.S. Inflation Data and Fed Speak
June S&P 500 E-Mini futures are up + this morning as trading resumes after Memorial Day holiday. In Friday's trading session, Wall Street's major averages closed higher. Deckers Outdoor was the top percentage gainer on the S&p 500 and top percentage loser on the Nasdaq 100. The release of the Fed's favorite inflation gauge later in the week will be the main highlight.
Barchart · 05/28 04:34
Weekly Report: what happened at CTMX last week (0520-0524)?
Weekly Report · 05/27 09:17
Weekly Report: what happened at CTMX last week (0513-0517)?
Weekly Report · 05/20 09:16
CytomX Therapeutics Announces New Employment Inducement Grants
CytomX Therapeutics, Inc. Granted two new employees options to purchase 130,000 shares of the Company's common stock. The Company is a leader in the field of masked, conditionally activated biologics. The company granted the options on May 15, 2024.
Barchart · 05/16 15:15
Weekly Report: what happened at CTMX last week (0506-0510)?
Weekly Report · 05/13 09:16
More
Webull provides a variety of real-time CTMX stock news. You can receive the latest news about Cytomx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.